International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder

Crunelle, Cleo L.; van den Brink, Wim; Moggi, Franz; Konstenius, Maija; Franck, Johan; Levin, Frances R.; van de Glind, Geurt; Demetrovics, Zsolt; Coetzee, Corné; Luderer, Mathias; Schellekens, Arnt; Matthys, Frieda (2018). International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European addiction research, 24(1), pp. 43-51. Karger 10.1159/000487767

Text Crunelle et al. EAR 2018.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (204kB) | Request a copy

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.

Interest & Impact

Downloads

4 since deposited on 19 Apr 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item